Related Experiment Video
Updated: Jun 27, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into
Theodora Katopodi1, Savvas Petanidis1,2, Eirini Grigoriadou1
1Laboratory of Medical Biology and Genetics, Department of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Abstract:
Extensive research into mRNA vaccines for cancer therapy in preclinical and clinical trials has prepared the ground for the quick development of immune-specific mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and are an attractive choice for future cancer immunotherapy. Ideal personalized tumor-dependent mRNA vaccines could stimulate both humoral and cellular immunity by overcoming cancer-induced immune suppression and tumor relapse. The stability, structure, and distribution strategies of mRNA-based vaccines have been improved by technological innovations, and patients with diverse tumor types are now being enrolled in numerous clinical trials investigating mRNA vaccine therapy. Despite the fact that therapeutic mRNA-based cancer vaccines have not yet received clinical approval, early clinical trials with mRNA vaccines as monotherapy and in conjunction with checkpoint inhibitors have shown promising results. In this review, we analyze the most recent clinical developments in mRNA-based cancer vaccines and discuss the optimal platforms for the creation of mRNA vaccines. We also discuss the development of the cancer vaccines' clinical research, paying particular attention to their clinical use and therapeutic efficacy, which could facilitate the design of mRNA-based vaccines in the near future.
Insights
Messenger RNA (mRNA) cancer vaccines are well-tolerated and show promise for immunotherapy. Ongoing clinical trials explore personalized mRNA vaccines to overcome immune suppression and improve therapeutic efficacy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Messenger RNA (mRNA) vaccine technology, rapidly advanced during the COVID-19 pandemic, shows significant potential for cancer therapy.
- Therapeutic mRNA cancer vaccines are well-tolerated and represent a promising avenue for future cancer immunotherapy strategies.
- Technological innovations have enhanced mRNA vaccine stability, structure, and delivery, facilitating broader clinical application.
Purpose of the Study:
- To review recent clinical developments in mRNA-based cancer vaccines.
- To discuss optimal platforms for mRNA vaccine development.
- To analyze clinical use and therapeutic efficacy for future vaccine design.
Main Methods:
- Review of preclinical and clinical trial data on mRNA cancer vaccines.
- Analysis of technological advancements in mRNA vaccine platforms.
- Examination of clinical trial outcomes for monotherapy and combination treatments.
Main Results:
- Early clinical trials demonstrate promising results for mRNA vaccines, both alone and with checkpoint inhibitors.
- mRNA vaccines have shown potential in stimulating humoral and cellular immunity and overcoming tumor-induced immune suppression.
- Numerous clinical trials are enrolling patients with diverse tumor types to investigate mRNA vaccine therapy.
Conclusions:
- Therapeutic mRNA cancer vaccines are a viable option for immunotherapy, despite lacking full clinical approval.
- Personalized, tumor-dependent mRNA vaccines could overcome immune suppression and tumor relapse.
- Further research and clinical trials are essential to optimize the design and application of mRNA-based cancer vaccines.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

